| Objective To retrospectively evaluate the clinical efficacy and safety of zoledronic acid (ZOL) and alendronate sodium (ALN) in patients with osteoporotic hip fractures. Methods Elderly patients who received zoledronic acid and alendronate sodium for at least 1 year were selected as subjects from the patients with osteoporotic hip fractures, who went to the clinic from January 2016 to October 2017, which were divided into observation group(ZOL treated) and control group(ALN treated). Visual analogue scale ( VAS), hip bone mineral density（BMD）, bone metabolism markers, the incidence of adverse reactions and recurrent osteoporotic fracture incidence in the two groups were measured at baseline and after one year treatment respectively．Results After one year treatment, BMD significant increased, the VAS score, procollagen type I amino terminal propeptide （PINP） and collagen degradation products（CTX）levels were significantly decreased than those before treatment（respectively P<0.05）.Compared with the control group, the VAS score and CTX were significantly lower in the observation group (P<0.05). There was no statistically significant difference in bone mineral density, PINP, incidence of adverse drug reactions and recurrent fractures between the two groups (P>0.05). Conclusion Both zoledronic acid and alendronate can significantly increase bone mineral density and have good safety performance. However, zoledronic acid is superior to alendronate in reducing bone pain symptoms after fracture, improving bone metabolism and improving patient compliance. |